Medical technology and radiopharmaceutical company Perspective Therapeutics has enrolled the first patient cohort in its Phase I/IIa dose escalation study of ²¹²Pb-VMT01 to treat MC1R-positive metastatic melanoma.
Clinical Trials
Neoadjuvant Daromun Meets Primary End Point of RFS in Melanoma
A trial of intratumoral daromun and surgical resection for the treatment of patients with locally advanced, fully resectable melanoma, showed a clinically meaningful improvement compared with surgery alone.
Lifileucel Demonstrates Efficacy in Advanced Mucosal Melanoma Following Progression on Immune Checkpoint Inhibitors
Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.
Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.